![Samir Shah](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Samir Shah
Directeur/Bestuurslid bij
VIVORYON THERAPEUTICS N.V.
Vermogen: - $ op 30-09-2026
Profiel
Dr. Samir Shah is on the Board of Directors at Vivoryon Therapeutics NV.
Dr. Shah was previously employed as a Global Head-Investor Relations by Novartis AG.
He received his MBA from the University of Warwick and a doctorate degree from The University of Sheffield.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2025 | 0 ( -.--% ) | - $ | 30-09-2026 |
Actieve functies van Samir Shah
| Bedrijven | Functie | Begin |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Directeur/Bestuurslid | 01-01-2022 |
Eerdere bekende functies van Samir Shah
| Bedrijven | Functie | Einde |
|---|---|---|
| NOVARTIS AG | Investor Relations Contact | - |
Opleiding van Samir Shah
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
94
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
The University of Sheffield
 The University of Sheffield Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Warwick
 University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivoryon Therapeutics NV
 Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
